Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Net Margin (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Net Margin for 14 consecutive years, with 64.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 6730.0% year-over-year to 64.13%, compared with a TTM value of 106.64% through Dec 2025, up 5064.0%, and an annual FY2025 reading of 125.19%, up 4610.0% over the prior year.
  • Net Margin was 64.13% for Q4 2025 at Enanta Pharmaceuticals, up from 122.9% in the prior quarter.
  • Across five years, Net Margin topped out at 64.13% in Q4 2025 and bottomed at 347.41% in Q3 2021.
  • Average Net Margin over 5 years is 154.28%, with a median of 133.29% recorded in 2023.
  • The sharpest move saw Net Margin tumbled -23210bps in 2021, then surged 21763bps in 2022.
  • Year by year, Net Margin stood at 108.92% in 2021, then dropped by -13bps to 122.9% in 2022, then tumbled by -51bps to 185.56% in 2023, then grew by 29bps to 131.43% in 2024, then soared by 51bps to 64.13% in 2025.
  • Business Quant data shows Net Margin for ENTA at 64.13% in Q4 2025, 122.9% in Q3 2025, and 99.68% in Q2 2025.